Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin®): A prospective study of 50 patients

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 6, 2007, Pages 1115-1124

  Borel Derlon, A ^a   Federici, A B ^b,j   Roussel Robert, V ^c   Goudemand, J ^d   Lee, C A ^e   Scharrer, I ^f   Rothschild, C ^g   Berntorp, E ^h   Henriet, C ⁱ   Tellier, Z ⁱ   Bridey, F ⁱ   Mannucci, Pier M ^b,j  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF MILAN   (Italy)

^c APHP ^*  (France)

^d UNIV LILLE   (France)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h LUND UNIVERSITY   (Sweden)

ⁱ Laboratoire Francais du Fractionnement et des Biotechnologies   (France)

^j FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

more..

Author keywords

von Willebrand disease; von Willebrand factor; von Willebrand factor concentrate

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; RISTOCETIN; TRANEXAMIC ACID; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CONCENTRATE; WILFACTIN;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CHEMOPROPHYLAXIS; CHILD; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG PURITY; DRUG RESPONSE; DRUG SAFETY; EUROPE; FEMALE; FRANCE; HEMARTHROSIS; HEMOSTASIS; HUMAN; MALAISE; MALE; MUCOSAL BLEEDING; MULTICENTER STUDY; MUSCLE BLEEDING; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; THROMBOSIS; VEIN DISEASE; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FACTOR VIII; FEMALE; HEMORRHAGE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; SAFETY; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 34250169072     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02562.x     Document Type: Article

References (23)

1. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
2. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, et.al. Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-14.
3. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first 20years. Blood 1997; 20: 2515-21.
4. Burnouf-Radosevich M, Burnouf T. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. Vox Sang 1992; 62: 1-11.
5. Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M. Clinical and biological evaluation in von Willebrand disease of a von Willebrand factor concentrate with low factor VIII activity. Br J Haematol 1992; 80: 214-21.
6. Meriane F, Zerhouni L, Djeha N, Goudemand M, Mazurier C. Biological effects of S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease. Blood Coagul Fibrinolysis 1993; 4: 1023-9.
7. Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand disease with a VHP vWF concentrate: The French experience. Haemophilia 1998; 4 (Suppl.3): 48-52.
8. Mazurier C, Poulle M, Samor B, Hilbert L, Chtourou S. In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang 2004; 86: 100-4.
9. Goudemand J, Scharrer I, Berntorp E, Lee CA, Borel-Derlon A, Stieltjes N, Caron C, Scherrmann JM, Bridey F, Tellier Z, Federici AB, Mannucci PM. Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus inactivation/removal methods. J Thromb Haemost 2005; 3: 1-9.
10. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: Results from current studies and surveys. Blood Coagul Fibrinolysis 2005; 16 (Suppl. 1): S17-21.
11. Cox Gill J, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P®): Use of ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003; 9: 688-95.
12. Mannucci PM, Chediak J, Hanna W, Bymes J, Ledford M, Ewenstein BM, Retzios AD, Kapelan BA, Schwartz RS, Kessler C, the Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 2002; 99: 450-6.
13. Thompson AR, Cox Gill J, Ewenstein BM, Mueller-Velten G, Schwartz BA. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P®). Haemophilia 2004; 10: 42-51.
14. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16: S23-6.
15. Federici AB, Gianniello F, Canciani MT, Mannucci PM. Secondary long-term prophylaxis in severe patients with von Willebrand disease: An Italian cohort study. Blood 2005; 106: 507a, abstract 1782.
16. Mannucci PM, Ruggeri ZM, Ciavarella N, Kazatchkine MD, Mowbray JF. Precipitating antibodies to factor VIII/von Willebrand Factor in von Willebrand Disease: Effect on replacement therapy. Blood 1981; 57: 25-31.
17. Brown KE, Young NS, Liu JM. Molecular, cellular and clinical aspects of parvovirus infection. Crit Rev Oncol Hematol 1994; 16: 1-31.
18. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995; 345: 152-5.
19. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-62.
20. Martinelli I. von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 2005; 42: 49-55.
21. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88: 378-9.
22. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351: 683-94.
23. Makris M, Calvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand disease. Thromb Haemost 2002; 88: 387-8.